Trial Profile
Anlotinib hydrochloride plus docetaxel versus docetaxel alone for the treatment of advanced non-squamous non-small-cell lung cancer after system chemotherapy: a multicentre randomised controlld clinical trial
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2018
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Jul 2018 New trial record